Acute myeloid leukemia with 11q23/MLL rearrangement after 'FCR' regimen for chronic lymphocytic leukemia

Eur J Haematol. 2012 Nov;89(5):430-1. doi: 10.1111/ejh.12001. Epub 2012 Aug 24.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Base Sequence
  • Chromosomes, Human, Pair 11 / genetics*
  • Chromosomes, Human, Pair 9 / genetics
  • Cyclophosphamide / administration & dosage
  • Cyclophosphamide / adverse effects
  • DNA Probes / genetics
  • Gene Rearrangement
  • Histone-Lysine N-Methyltransferase
  • Humans
  • In Situ Hybridization, Fluorescence
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Leukemia, Myeloid, Acute / etiology*
  • Leukemia, Myeloid, Acute / genetics*
  • Male
  • Middle Aged
  • Myeloid-Lymphoid Leukemia Protein / genetics*
  • Neoplasms, Second Primary / etiology*
  • Neoplasms, Second Primary / genetics*
  • Rituximab
  • Translocation, Genetic
  • Vidarabine / administration & dosage
  • Vidarabine / adverse effects
  • Vidarabine / analogs & derivatives

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • DNA Probes
  • KMT2A protein, human
  • Myeloid-Lymphoid Leukemia Protein
  • Rituximab
  • Cyclophosphamide
  • Histone-Lysine N-Methyltransferase
  • Vidarabine
  • fludarabine